Nanostart-owned MagForce Publishes Study Results of Nano-Cancer® Therapy
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
The Journal of Neuro-Oncology has published the results of a clinical study by MagForce Nanotechnologies AG, a majority-owned portfolio company of Nanostart AG, demonstrating the effectiveness of its Nano-Cancer® therapy in the treatment of patients with recurrent glioblastoma. These clinical trials served as the basis for EU regulatory approval, received in June 2010, of this revolutionary new approach to treating solid tumors.
The Journal of Neuro-Oncology is an international multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research.
With this publication in the Journal of Neuro-Oncology, the detailed results of clinical trials demonstrating the effectiveness of Nano-Cancer® therapy have now for the first time been shared with the international scientific and medical community.
According to statements made by Dr. Peter Heinrich, CEO of MagForce Nanotechnologies, the company is currently planning further strategic steps. Product introduction, starting with the German market, is schedule to commence in the first quarter of 2011. Sale and marketing teams for product commercialization, as well as the needed infrastructure, are currently being put in place. In addition, other clinical trials will be initiated, and the company will be structured to optimally serve the international market.
The full journal article, entitled “Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.”
The study reported on the treatment of 59 cancer patients suffering from recurrent glioblastoma, a particularly aggressive form of brain tumor. Using Nano-Cancer® therapy in conjunction with radiotherapy, the median survival time of the patient group was 13.4 months, compared to 6.2 months using existing conventional therapies in a control study. The median survival time was thus more than doubled, a significant increase. In addition, the new therapy offers the advantage of minimal side effects and reduced patient discomfort compared to existing therapeutic alternatives.
The Journal of Neuro-Oncology is an international multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research.
With this publication in the Journal of Neuro-Oncology, the detailed results of clinical trials demonstrating the effectiveness of Nano-Cancer® therapy have now for the first time been shared with the international scientific and medical community.
According to statements made by Dr. Peter Heinrich, CEO of MagForce Nanotechnologies, the company is currently planning further strategic steps. Product introduction, starting with the German market, is schedule to commence in the first quarter of 2011. Sale and marketing teams for product commercialization, as well as the needed infrastructure, are currently being put in place. In addition, other clinical trials will be initiated, and the company will be structured to optimally serve the international market.
The full journal article, entitled “Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.”
The study reported on the treatment of 59 cancer patients suffering from recurrent glioblastoma, a particularly aggressive form of brain tumor. Using Nano-Cancer® therapy in conjunction with radiotherapy, the median survival time of the patient group was 13.4 months, compared to 6.2 months using existing conventional therapies in a control study. The median survival time was thus more than doubled, a significant increase. In addition, the new therapy offers the advantage of minimal side effects and reduced patient discomfort compared to existing therapeutic alternatives.
